{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:24:12Z","timestamp":1789118652201,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pharmacist-led medication reviews are increasingly recognised for generating cost savings within the hospital. However, no cost-analysis has investigated the budget impact of junior pharmacists conducting medication reviews under supervision of clinical pharmacists, nor included recommendations to start-, increase-, or monitor medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the budget impact of medication reviews by supervised junior pharmacists across hospital wards, explore budget impact differences between drug classes, and identify patient predictors that potentially influence the budget impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Data of medication reviews were collected over a 19-month period in patients with polypharmacy (\u2265\u20095 medications) who had at least one additional risk factor. We developed a cost model over a one-year horizon, from the hospital perspective. Intervention costs were derived from measured labour time per medication review and salary of junior- and clinical pharmacists. Cost avoidance from potential preventable medication-related readmissions were based on admission time, admission costs and an estimate of preventable medication-related admissions (4.8%). Costs and savings from medication recommendations were aggregated using drug price per daily defined dose and its predicted days of therapy per year, and clustered by drug class. Scenario analyses tested the robustness of medication recommendation savings to account for effectively implemented and additional monitoring recommendations. Patient predictors of budget impact related to medication recommendations were assessed using multivariable linear regression, including age, gender, eGFR, acute admission, medication count, comorbidity, expensive drugs, and ward type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We collected 271 medication reviews, including 1,689 medication recommendations. Per-patient budget impact was negative for the\u00a0intervention (\u20ac104 costs), but positive for medication recommendations (\u20ac46 savings), and preventable medication-related readmissions (\u20ac239 savings). Total estimated savings were \u20ac181 per patient, and \u20ac688,000 when upscaled hospital-wide. Opiates, beta receptor agonists, corticosteroids, urological drugs, and muscarine receptor antagonists generated 43% of medication recommendation savings. Erythropoietic growth factors, SGLT2 inhibitors, etanercept, etravirine, and calcium\/vitamin D formulations generated 70% of medication recommendation costs. No significant associations were found between any of the included patient characteristics and budget impact related to medication recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Junior pharmacist-led medication reviews provide a modest cost-saving intervention from the hospital perspective, demonstrating savings across clinical populations with polypharmacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02190-4","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:29:05Z","timestamp":1784273345000},"page":"2073-2081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Budget impact analysis of medication reviews by junior pharmacists in polypharmacy patients: a hospital perspective"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0327-7990","authenticated-orcid":false,"given":"Toon","family":"Hectors","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1660-6389","authenticated-orcid":false,"given":"Thirza","family":"Kooijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-2477","authenticated-orcid":false,"given":"Marit","family":"van Barreveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7125-2449","authenticated-orcid":false,"given":"Marianne","family":"Kuijvenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8798-6726","authenticated-orcid":false,"given":"Patty","family":"Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-2279","authenticated-orcid":false,"given":"Rik","family":"Olde Engberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2190_CR1","unstructured":"Da Costa FA, Blondal AB, Chapichadze Z, et al. Guidelines on Medication Review. Strasbourg: European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe; 2024. https:\/\/freepub.edqm.eu\/. Accessed 25.01.2025."},{"key":"2190_CR2","unstructured":"World Health Organization. Medication Safety in Polypharmacy: Technical Report. WHO\/UHC\/SDS\/2019.11. Geneva: World Health Organization; 2019. https:\/\/iris.who.int\/handle\/10665\/325454. Accessed 25.01.2025."},{"key":"2190_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1365-2125.2006.02698.x","volume":"63","author":"RL Howard","year":"2007","unstructured":"Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63:136\u201347. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02698.x.","journal-title":"Br J Clin Pharmacol"},{"key":"2190_CR4","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/archinternmed.2008.3","volume":"168","author":"AJ Leendertse","year":"2008","unstructured":"Leendertse AJ, Egberts ACG, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168:1890\u20136. https:\/\/doi.org\/10.1001\/archinternmed.2008.3.","journal-title":"Arch Intern Med"},{"key":"2190_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/1060028019886846","volume":"54","author":"V Alves-Concei\u00e7\u00e3o","year":"2020","unstructured":"Alves-Concei\u00e7\u00e3o V, Rocha KSS, Silva FVN, et al. Are clinical outcomes associated with medication regimen complexity? A systematic review and meta-analysis. Ann Pharmacother. 2020;54:301\u201313. https:\/\/doi.org\/10.1177\/1060028019886846.","journal-title":"Ann Pharmacother"},{"key":"2190_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/ajhp\/zxz284","volume":"77","author":"LJ Anderson","year":"2020","unstructured":"Anderson LJ, Nuckols TK, Coles C, et al. A systematic overview of systematic reviews evaluating medication adherence interventions. Am J Health Syst Pharm. 2020;77:138\u201347. https:\/\/doi.org\/10.1093\/ajhp\/zxz284.","journal-title":"Am J Health Syst Pharm"},{"key":"2190_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1477-7525-9-95","volume":"9","author":"I Nordin Olsson","year":"2011","unstructured":"Nordin Olsson I, Runnamo R, Engfeldt P. Medication quality and quality of life in the elderly, a cohort study. Health Qual Life Outcomes. 2011;9:95. https:\/\/doi.org\/10.1186\/1477-7525-9-95.","journal-title":"Health Qual Life Outcomes"},{"key":"2190_CR8","doi-asserted-by":"publisher","first-page":"102237","DOI":"10.1016\/j.arr.2024.102237","volume":"95","author":"N Veronese","year":"2024","unstructured":"Veronese N, Gallo U, Boccardi V, et al. Efficacy of deprescribing on health outcomes: an umbrella review of systematic reviews with meta-analysis of randomized controlled trials. Ageing Res Rev. 2024;95:102237. https:\/\/doi.org\/10.1016\/j.arr.2024.102237.","journal-title":"Ageing Res Rev"},{"key":"2190_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ijpp\/riad025","volume":"31","author":"H Omuya","year":"2023","unstructured":"Omuya H, Nickel C, Wilson P, et al. A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy. Int J Pharm Pract. 2023;31:349\u201368. https:\/\/doi.org\/10.1093\/ijpp\/riad025.","journal-title":"Int J Pharm Pract"},{"key":"2190_CR10","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1111\/jgs.19035","volume":"72","author":"M Carollo","year":"2024","unstructured":"Carollo M, Crisafulli S, Vitturi G, et al. Clinical impact of medication review and deprescribing in older inpatients: a systematic review and meta-analysis. J Am Geriatr Soc. 2024;72:3219\u201338. https:\/\/doi.org\/10.1111\/jgs.19035.","journal-title":"J Am Geriatr Soc"},{"key":"2190_CR11","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/bcp.13085","volume":"82","author":"P Renaudin","year":"2016","unstructured":"Renaudin P, Boyer L, Esteve MA, et al. Do pharmacist-led medication reviews in hospitals help reduce hospital readmissions? A systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:1660\u201373. https:\/\/doi.org\/10.1111\/bcp.13085.","journal-title":"Br J Clin Pharmacol"},{"key":"2190_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11096-021-01323-1","volume":"44","author":"S Wilkes","year":"2022","unstructured":"Wilkes S, Zaal RJ, Abdulla A, et al. A cost\u2013benefit analysis of hospital-wide medication reviews: a period prevalence study. Int J Clin Pharm. 2022;44:138\u201345. https:\/\/doi.org\/10.1007\/s11096-021-01323-1.","journal-title":"Int J Clin Pharm"},{"key":"2190_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s11096-023-01683-w","volume":"46","author":"M Jermini","year":"2024","unstructured":"Jermini M, Fonzo-Christe C, Blondon K, et al. Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis. Int J Clin Pharm. 2024;46:496\u2013505. https:\/\/doi.org\/10.1007\/s11096-023-01683-w.","journal-title":"Int J Clin Pharm"},{"key":"2190_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-024-11346-9","volume":"24","author":"RN Rahman","year":"2024","unstructured":"Rahman RN, Polinder S, Nikolik B, et al. Medication reviews by emergency department pharmacists in patients hospitalised for an adverse drug event: a cost study. BMC Health Serv Res. 2024;24:1\u20139. https:\/\/doi.org\/10.1186\/s12913-024-11346-9.","journal-title":"BMC Health Serv Res"},{"key":"2190_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jac5.70034","volume":"8","author":"B De Los Santos","year":"2018","unstructured":"De Los Santos B, Kim M, Alsharif A, et al. A systematic review of economic evaluations of clinical pharmacy services in the United States: 2018\u20132022. J Am Coll Clin Pharm. 2018;8:385\u201397. https:\/\/doi.org\/10.1002\/jac5.70034.","journal-title":"J Am Coll Clin Pharm"},{"key":"2190_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/2284240318807726","author":"A Kearney","year":"2018","unstructured":"Kearney A, Walsh EK, Kirby A, et al. A budget impact analysis of a clinical medication review of patients in an Irish university teaching hospital. Glob Reg Health Technol Assess. 2018. https:\/\/doi.org\/10.1177\/2284240318807726.","journal-title":"Glob Reg Health Technol Assess"},{"key":"2190_CR17","doi-asserted-by":"publisher","first-page":"1244151","DOI":"10.3389\/fphar.2023.1244151","volume":"14","author":"K Urba\u0144czyk","year":"2023","unstructured":"Urba\u0144czyk K, Guntschnig S, Antoniadis V, et al. Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes. Front Pharmacol. 2023;14:1244151. https:\/\/doi.org\/10.3389\/fphar.2023.1244151.","journal-title":"Front Pharmacol"},{"key":"2190_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/ejhpharm-2016-001185","volume":"25","author":"LM West","year":"2018","unstructured":"West LM, Vetter-Kerkhoff C, Miljkovic N, et al. Is there a need for a hospital pharmacy common training framework? Review of the literature on the impact of educational interventions on health outcome. Eur J Hosp Pharm. 2018;25:6\u20139. https:\/\/doi.org\/10.1136\/ejhpharm-2016-001185.","journal-title":"Eur J Hosp Pharm"},{"key":"2190_CR19","volume-title":"KNMP-richtlijn Medicatiebeoordeling [KNMP guideline Medication Review]","author":"Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie","year":"2013","unstructured":"Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie. KNMP-richtlijn Medicatiebeoordeling [KNMP guideline Medication Review]. The Hague: KNMP; 2013."},{"key":"2190_CR20","unstructured":"Leendertse A, van den Bemt PMLA, Verduijn MM, et al. Bijlage 1: Gestructureerde medicatiebeoordeling \u2014 STRIP-methode. Multidisciplinaire Richtlijn Polyfarmacie bij Ouderen [Structured medication review \u2014 STRIP method. Multidisciplinary Guideline Polypharmacy in the Elderly]. 2013. pp. 74\u20137."},{"key":"2190_CR21","unstructured":"Castor EDC. Castor \u2014 electronic data capture platform. https:\/\/www.castoredc.com\/. Accessed 26.06.2025."},{"key":"2190_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25:10\u201331. https:\/\/doi.org\/10.1016\/j.jval.2021.10.008.","journal-title":"Value Health"},{"key":"2190_CR23","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu. Ziekenhuiszorg | Aanbod | Instellingen | Volksgezondheid en Zorg [Hospital care | Supply | Institutions]. https:\/\/www.vzinfo.nl\/ziekenhuiszorg\/aanbod\/instellingen. Accessed 31.01.2026."},{"key":"2190_CR24","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu. Ziekenhuiszorg | Gebruik | Volksgezondheid en Zorg [Hospital care | Use]. https:\/\/www.vzinfo.nl\/ziekenhuiszorg\/gebruik. Accessed 31.01.2026."},{"key":"2190_CR25","doi-asserted-by":"publisher","first-page":"1357171","DOI":"10.3389\/fphar.2024.1357171","volume":"15","author":"AA Alqurain","year":"2024","unstructured":"Alqurain AA, Albaharnah M, Al Zayer S, et al. The prevalence of polypharmacy and hyper-polypharmacy among middle-aged vs. older patients in Saudi Arabia: a cross-sectional study. Front Pharmacol. 2024;15:1357171. https:\/\/doi.org\/10.3389\/fphar.2024.1357171.","journal-title":"Front Pharmacol"},{"key":"2190_CR26","doi-asserted-by":"publisher","first-page":"e078890","DOI":"10.1136\/bmjopen-2023-078890","volume":"14","author":"F Jonsdottir","year":"2024","unstructured":"Jonsdottir F, Blondal AB, Gudmundsson A, et al. The association of degree of polypharmacy before and after among hospitalised internal medicine patients and clinical outcomes: a retrospective, population-based cohort study. BMJ Open. 2024;14:e078890. https:\/\/doi.org\/10.1136\/bmjopen-2023-078890.","journal-title":"BMJ Open"},{"key":"2190_CR27","unstructured":"Hakkaart-Van Roijen L, Peeters S, Kanters T. Kostenhandleiding voor economische evaluaties in de gezondheidszorg: methodologie en referentieprijzen [Dutch manual for costing in economic evaluations: methodology and reference prices]. In opdracht van Zorginstituut Nederland; 2024."},{"key":"2190_CR28","unstructured":"Centraal Bureau voor de Statistiek. Consumentenprijzen; prijsindex 2015=100 [Consumer prices; price index 2015=100]. https:\/\/www.cbs.nl\/nl-nl\/cijfers\/detail\/83131NED. Accessed 28.01.2026."},{"key":"2190_CR29","volume-title":"CAO Universitair Medische Centra 2024\u20132025 [Collective Agreement University Medical Centres 2024\u20132025]","author":"Nederlandse Federatie van Universitaire Medische Centra","year":"2024","unstructured":"Nederlandse Federatie van Universitaire Medische Centra. CAO Universitair Medische Centra 2024\u20132025 [Collective Agreement University Medical Centres 2024\u20132025]. Amsterdam: NFU; 2024."},{"key":"2190_CR30","unstructured":"Medicijnkosten.nl. [Medicationcosts.nl] https:\/\/www.medicijnkosten.nl\/. Accessed 26.06.2025."},{"key":"2190_CR31","volume-title":"Farmacotherapeutisch Kompas","author":"Farmacotherapeutisch Kompas","year":"2016","unstructured":"Farmacotherapeutisch Kompas. Farmacotherapeutisch Kompas. Amstelveen: Zorginstituut Nederland; 2016."},{"key":"2190_CR32","volume-title":"ODV-tarieven Amsterdam UMC 2023 [ODV rates Amsterdam UMC 2023]","author":"UMC Amsterdam","year":"2023","unstructured":"Amsterdam UMC. ODV-tarieven Amsterdam UMC 2023 [ODV rates Amsterdam UMC 2023]. Amsterdam: Amsterdam UMC; 2023."},{"key":"2190_CR33","doi-asserted-by":"publisher","first-page":"105462","DOI":"10.1016\/j.jamda.2024.105462","volume":"26","author":"NC Ramsey","year":"2025","unstructured":"Ramsey NC, Peterson GM, Mirkazemi C, et al. Factors influencing medical prescribers\u2019 acceptance of pharmacists\u2019 recommendations in non-hospitalized older adults: a systematic review and meta-analysis. J Am Med Dir Assoc. 2025;26:105462. https:\/\/doi.org\/10.1016\/j.jamda.2024.105462.","journal-title":"J Am Med Dir Assoc"},{"key":"2190_CR34","volume-title":"Ziekenhuissector op een kantelpunt: gebrek aan financieel perspectief bedreigt transformatie in de zorg [Hospital sector at a tipping point: lack of financial perspective threatens transformation in care]","author":"V Eversdijk","year":"2024","unstructured":"Eversdijk V, Tagage M, Jongsma EJ, et al. Ziekenhuissector op een kantelpunt: gebrek aan financieel perspectief bedreigt transformatie in de zorg [Hospital sector at a tipping point: lack of financial perspective threatens transformation in care]. Amsterdam: BDO Accountants & Adviseurs; 2024."},{"key":"2190_CR35","unstructured":"Erasmus MC. Annual Report 2024: Erasmus MC prepares for long-term investments in the healthcare of tomorrow. Rotterdam: Erasmus MC; 2024. Accessed 30.01.2026. https:\/\/www.erasmusmc.nl\/en\/pages\/about-erasmusmc\/content\/annual-report."},{"key":"2190_CR36","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/archinte.159.19.2306","volume":"159","author":"ST McMullin","year":"1999","unstructured":"McMullin ST, Hennenfent JA, Ritchie DJ, et al. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999;159:2306\u20139. https:\/\/doi.org\/10.1001\/archinte.159.19.2306.","journal-title":"Arch Intern Med"},{"key":"2190_CR37","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s11239-016-1455-z","volume":"43","author":"MK Wychowski","year":"2016","unstructured":"Wychowski MK, Ruscio CI, Kouides PA, et al. The scope and value of an anticoagulation stewardship program at a community teaching hospital. J Thromb Thrombolysis. 2016;43:380\u20136. https:\/\/doi.org\/10.1007\/s11239-016-1455-z.","journal-title":"J Thromb Thrombolysis"},{"key":"2190_CR38","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s13300-020-00868-0","volume":"11","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Ara\u00fajo F, Dores J, et al. Hospitalization costs due to hypoglycemia in patients with diabetes: a microcosting approach. Diabetes Ther. 2020;11:2237\u201348. https:\/\/doi.org\/10.1007\/s13300-020-00868-0.","journal-title":"Diabetes Ther"},{"key":"2190_CR39","doi-asserted-by":"publisher","first-page":"e0594","DOI":"10.1097\/CCE.0000000000000594","volume":"3","author":"MA Rech","year":"2021","unstructured":"Rech MA, Gurnani PK, Peppard WJ, et al. Pharmacist avoidance or reductions in medical costs in critically ill adults: PHARM-CRIT study. Crit Care Explor. 2021;3:e0594. https:\/\/doi.org\/10.1097\/CCE.0000000000000594.","journal-title":"Crit Care Explor"},{"key":"2190_CR40","doi-asserted-by":"publisher","first-page":"n1585","DOI":"10.1136\/bmj.n1585","volume":"374","author":"MR Blum","year":"2021","unstructured":"Blum MR, Sallevelt BTGM, Spinewine A, et al. Optimizing therapy to prevent avoidable hospital admissions in multimorbid older adults (OPERAM): cluster randomised controlled trial. BMJ. 2021;374:n1585. https:\/\/doi.org\/10.1136\/bmj.n1585.","journal-title":"BMJ"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02190-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02190-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02190-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:40Z","timestamp":1789117120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02190-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2190"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02190-4","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethics Review Committee of the Amsterdam University Medical Centre (UMC) approved the present study (2024.1024).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}